2. Protein Tyrosine Kinase/RTK
  3. FGFR
  4. Bemarituzumab

Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr. : 1952272-74-0

Größe Preis Verfügbarkeit Menge
Kostenlose Probe (100 μg)   Jetzt bewerben  
1 mg Auf Lager
5 mg Auf Lager
10 mg Auf Lager
50 mg   Angebot einholen  
100 mg   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Bemarituzumab Related Antibodies

Top Publications Citing Use of Products

  • Biologische Aktivität

  • Reinheit & Dokumentation

  • Verweise

  • Kundenbewertung

Beschreibung

Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer[1][2].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

FGFR2/CD332
In Vitro

Bemarituzumab (0.001-100 μg/mL, 30 min) inhibits FGF7-induced FGFR2 phosphorylation and cell proliferation in a concentration-dependent manner in the SNU-16 human gastric cancer cells, reaching a maximal value at ≥6.25 μg/mL[2].
Bemarituzumab exhibits immune cell-mediated killing of tumor cells overexpressing FGFR2b[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bemarituzumab Related Antibodies
In Vivo

Bemarituzumab (1-5 mg/kg; i.v.; twice a week) inhibits tumor growth in a dose-dependent manner and causes tumor regression in some mice in the xenograft mouse model of OCUM-2M human gastric cancer cells[2].
Bemarituzumab (5 mg/kg; i.p.; twice a week) combined with 5-fluorouracil (HY-90006) and Oxaliplatin (HY-17371) significantly inhibits tumor growth more than monotherapy and does not increase chemotherapy-related toxicity in the OCUM-2M gastric cancer xenograft model[2].
Bemarituzumab (10 mg/kg; i.p.; biweekly) significantly reduces tumor burden, recruits NK cells, and increases PD-L1-expressing cells and CD3-positive T cells in the syngeneic 4T1 mouse mammary tumor model[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CB17 SCID mice (7-8 weeks old), xenograft model of OCUM-2M human gastric cancer cells[2]
Dosage: 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 3 mg/kg, 5 mg/kg (in PBS)
Administration: Intravenous injection, twice a week
Result: Inhibited tumor growth in a dose-dependent manner.
Inhibited and regressed tumor growth starting from a dose of 1 mg/kg.
Caused complete tumor regression in 1/15 mice at the 1.5 mg/kg and 2 mg/kg doses, 4/15 mice at the 3 mg/kg dose, and 6/15 mice at the 5 mg/kg dose by day 42.
Animal Model: Tg-ArcSwe transgenic mice (11-14 months old) harboring the APP Arctic mutation[3]
Dosage: 10 mg/kg
Administration: i.p., once weekly, for 4/13 weeks
Result: Achieved brain amyloid-β (Aβ) protofibril and cerebrospinal fluid (CSF) Aβ protofibrils/oligomers reduction.
Klinische Studie
Gene ID

2263  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molekulargewicht

143.86 kDa

CAS. Nr.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Bemarituzumab]
Versand

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Immobilized FGFR-2 alpha (IIIb) Protein, Human (HEK293, His, HY-P76336) can bind Bemarituzumab. The EC50 for this effect is 5.673 ng/mL.
Reinheit & Dokumentation

Purity: 99.82%

SDS (251 KB)

COA (232 KB) SDS-PAGE (70 KB) SEC-HPLC (121 KB)

Inhibitory Antibodies User Guide (603 KB)
Verweise
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Bemarituzumab Related Classifications

  • Molaritätsrechner

  • Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bemarituzumab1952272-74-0FGFRFibroblast growth factor receptorfirst-in-classhumanized IgG1 monoclonal antibodanticancermammary tumorInhibitorinhibitorinhibit

Ihre kürzlich angesehenen Produkte:

Online-Anfrage

Your information is safe with us. * Required Fields.

Produktname

  

Requested Quantity *

Name des Antragstellers *

 

Anrede

E-Mail-Addresse *

 

Telefonnummer *

Department

 

Name der Organisation *

City

Bundesland

Country or Region *

      

Bemerkungen

Massenanfrage

Inquiry Information

Produktname:
Bemarituzumab
Art. -Nr.:
HY-P99010
Menge:
MCE Japan Authorized Agent:

Kundenbewertung

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Produktname

  

Lot #

Name des Antragstellers *

 

E-Mail-Addresse *

Telefonnummer

 

Department *

Name der Organisation *

 

Country or Region *

Bemerkungen

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.